DOCK2: A novel FLT3/ITD leukemia drug target

Oncotarget. 2017 Sep 30;8(51):88253-88254. doi: 10.18632/oncotarget.21390. eCollection 2017 Oct 24.

Authors

Min Wu¹, Donald Small¹, Amy S Duffield¹

Affiliation

¹ Amy S. Duffield: Department of Pathology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, USA.

No abstract available

Keywords: DOCK2; FMS-like tyrosine kinase-3 (FLT3); Rac1; acute myeloid leukemia; internal tandem duplication.

Publication types

Editorial

Grants and funding

R01 CA090668/CA/NCI NIH HHS/United States